We kicked off the year high with our annual meeting, aligning on 2025 goals and celebrating our values. A highlight was honoring two exceptional employees with the CEO Award for their outstanding contributions. Here’s to a great year ahead!

President & CEO Lori Lyons-Williams & CMO Philippe Bishop will join a virtual fireside chat at the William Blair Radiopharma Conference to discuss the present & future of precision #radiotherapeutics. They will share insights into Abdera’s development plans & how our proprietary

We’re excited to see President & CEO Lori Lyons-Williams recognized as one of the Most Influential Women in Bay Area Business 2025 by San Francisco Business Times! Lori’s visionary leadership is helping drive Abdera’s mission forward, shaping the future of #cancer treatment. This recognition

Abdera co-founder and COO, Lana Janes, Ph.D., will present at the Stifel Virtual Targeted Oncology Forum. We look forward to continuing to share our mission in developing new precision #radiotherapeutics to treat a broad range of solid tumors.

Still feeling the momentum from yesterday’s CNBC Changemakers Summit, where our CEO Lori Lyons-Williams brought her trademark authenticity to a room full of trailblazers. Progress in biotech isn’t just science—it’s people. We’re proud to see her leading that conversation.

Our strength lies in the passionate people behind the mission. Every new team member adds a unique perspective & a shared drive to transform the way people living with cancer can be treated. With a commitment to impact and a mindset built for innovation, Sean is helping push our

We’re pleased to share that we have two presentations at the upcoming 2025 @aacr Annual Meeting. These include a trial in progress for our ongoing Phase 1 clinical trial for ABD-147, as well as the disclosure of our second lead program, ABD-320. Read more here:

The Abdera team was proud to attend #AACR25, where we presented a Trial-in-Progress for our Phase 1 study of ABD-147 and unveiled our second lead program, ABD-320. We're energized by the progress across #oncology and remain committed to advancing novel radiopharmaceutical

The San Francisco Business Times Most Influential Women Gala brought together some of the Bay Area’s boldest minds last night, including our CEO Lori Lyons-Williams, who continues to lead Abdera with vision and drive.  Congratulations to all the incredible leaders honored!

Targeted #radiotherapeutics has three components: a cancer-targeting molecule, a chelating agent that binds a radioisotope, & a linker connecting them. The goal is for the targeting molecule to seek out & bind tumor cells, delivering the radioisotope to destroy them & limit tumor

Details: businesswire.com/news/home/2025… We are pleased to welcome Rachael Brake as our Chief Scientific Officer. Rachael brings a wealth of experience that will help shape the next chapter of our clinical development efforts, & her leadership will be instrumental in delivering on our

Abdera CSO Rachael Brake was recently featured in STAT "Up and Down the Ladder", covering the latest comings & goings in biotech. The piece offers a glimpse beyond the title. Read more below. statnews.com/pharmalot/2025…

Abdera VP of CMC Radiopharmaceutical Development Kevin Roland is headed to the 4th #TRPSummit2025 next week! He’ll share insights on regulatory strategy and the tech driving scalable, sustainable production of next-gen #radiotherapeutics for solid tumors. We're proud to be

Next week at the 4th #TRPSummit2025, Abdera CTO Kawa Chiu takes the stage to chair Day 1 & weigh in on two panels, covering real-world evidence in RLT trial design & the future of talent in radiopharma. Kawa’s perspective is shaped by years at the forefront of targeted

Lung cancer doesn’t wait; it impacts hundreds of lives each day. Behind every diagnosis is a person with hopes, loved ones, & a future worth fighting for. On #WorldLungCancerDay, we honor those affected & reaffirm our commitment at Abdera to walk beside you through every step of

At Abdera, we’re building a community of innovators, leaders & changemakers dedicated to advancing targeted #radiotherapeutics. With a deep understanding of #oncology drug development & a clear vision for impact, Bryan is helping shape the future of our portfolio and the